BIT 2.53% 8.1¢ biotron limited

Biotron and Hep B

  1. 13,013 Posts.
    lightbulb Created with Sketch. 99
    Hepatitis B – Pipeline Review, Therapeutic Areas with Key Companies Abivax SA, Biotron, Celltrion, Kineta

    May 19, 2018 - by [email protected]
    Hepatitis B – Pipeline Review, H1 2018 is latest pipeline review released by HTF MI to provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, root cause analysis, mechanism of action (MoA), route of administration (RoA) and molecule type.
    Get Access to Sample PDF @: https://www.htfmarketreport.com/sample-report/1163827-hepatitis-b-pipeline-review-4
    If you are want to study the Hepatitis B or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs.
    Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
    Key Players included in the research study are Abivax SA, AiCuris GmbH & Co KG, AIMM Therapeutics BV, Akshaya Bio Inc, Alnylam Pharmaceuticals Inc, Altimmune Inc, Altravax Inc, Amarna Therapeutics BV, Arbutus Biopharma Corp, Arcturus Therapeutics Ltd, Arrowhead Pharmaceuticals Inc, Ascentage Pharma Group Corp Ltd, Assembly Biosciences Inc, Aucta Pharmaceuticals LLC, Beijing Kawin Technology Share-Holding Co Ltd, Beijing Minhai Biotechnology Co Ltd, Benitec Biopharma Ltd, Biological E Ltd, BioStar Pharmaceuticals Inc, Biotron Ltd, Bolder Biotechnology Inc, BrightGene Bio-Medical Technology Co Ltd, Bukwang Pharm Co Ltd, Cadila Healthcare Ltd, CaroGen Corp, Celltrion Inc, Chong Kun Dang Pharmaceutical Corp, Chongqing Zhifei Biological Products Co Ltd, Chromis Therapeutics Inc, Cocrystal Pharma Inc, ContraVir Pharmaceuticals Inc, CyTuVax BV, DelSiTech Ltd, Dicerna Pharmaceuticals Inc, Dong-A Socio Holdings Co Ltd, Ensemble Therapeutics Corp, Enyo Pharma SA, Excision BioTherapeutics Inc, F. Hoffmann-La Roche Ltd, GC Pharma, GeneCure LLC, GeoVax Labs Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Huons Global Co Ltd, Immunotope Inc, Indian Immunologicals Ltd, Inovio Pharmaceuticals Inc, Intellia Therapeutics Inc, Ionis Pharmaceuticals Inc, ISA Pharmaceuticals BV, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Johnson & Johnson, Kainos Medicine Inc, Kineta Inc, LG Chem Ltd, Microbiotix Inc, MultiCell Technologies Inc, Oncolys BioPharma Inc, Pfenex Inc, PharmaEssentia Corp, Profarma, Profectus BioSciences Inc, Qilu Pharmaceutical Co Ltd, Replicor Inc, Rodos BioTarget GmbH, Samjin Pharm Co Ltd, Sanofi Pasteur SA, Scynexis Inc, Shantha Biotechnics Pvt Ltd, Sino Biopharmaceutical Ltd, Spring Bank Pharmaceuticals Inc, TCM Biotech International Corp, Theravectys SA, THEVAX Genetics Vaccine USA Inc, Transgene SA, Vaccitech Ltd, Vaxine Pty Ltd, VBI Vaccines Inc, Vical Inc, ViroStatics srl & VLP Biotech Inc.
    Make inquiry before purchase @ https://www.htfmarketreport.com/enquiry-before-buy/1163827-hepatitis-b-pipeline-review-4
    The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
    Hepatitis B pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis.
    Buy this research report @ https://www.htfmarketreport.com/buy-now?format=1&report=1163827
    Extracts of Chapters from Hepatitis B – Pipeline Review, H1 2018
    Chapter 1 , to describe the definition , overview and Therapeutics Development of Hepatitis B.
    Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes.
    Chapter3, Therapeutics Assessment of Hepatitis B by Target, Mechanism of Action, Route of Administration and by Molecule Type.
    Chapter4, to display company profile involved in Therapeutics Development.
    Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Hepatitis B.
    Chapter 6,7, to describe Hepatitis B Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us.
    Objective of this study
    – To provides a snapshot of the global therapeutic landscape of Hepatitis B.
    – To reviews pipeline therapeutics for Hepatitis B by companies and universities/research institutes based on information derived from company and industry-specific sources.
    – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    – The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    – The pipeline guide reviews key companies involved in Hepatitis B therapeutics and enlists all their major and minor projects.
    – The pipeline guide evaluates Hepatitis B therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    – The guide encapsulates all the dormant and discontinued pipeline projects.
    – The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B
    Reasons to buy
    – Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    – Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    – Find and recognize significant and varied types of therapeutics under development for Hepatitis B.
    – Classify potential new clients or partners in the target demographic.
    – Develop tactical initiatives by understanding the focus areas of leading companies.
    – Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    – Formulate corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics.
    – Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    – Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Early buyers will receive 10% customization on reports. Read Detailed Index of full Research Study at @ https://www.htfmarketreport.com/reports/1163827-hepatitis-b-pipeline-review-4
    Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
    About Author:
    HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

    Contact US :
    Craig Francis (PR & Marketing Manager)
    HTF Market Intelligence Consulting Private Limited
    Unit No. 429, Parsonage Road Edison, NJ
    New Jersey USA – 08837
    Phone: +1 (206) 317 1218
    [email protected]
    Connect with us at

    https://www.linkedin.com/company/13388569/
    https://plus.google.com/u/0/ Htfmarketreportinsights
    https://www.facebook.com/htfmarketintelligence/
    https://twitter.com/htfmarketreport
 
watchlist Created with Sketch. Add BIT (ASX) to my watchlist
(20min delay)
Last
8.1¢
Change
0.002(2.53%)
Mkt cap ! $73.08M
Open High Low Value Volume
7.5¢ 8.1¢ 7.2¢ $87.51K 1.177M

Buyers (Bids)

No. Vol. Price($)
2 30000 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 312790 2
View Market Depth
Last trade - 15.39pm 28/03/2024 (20 minute delay) ?
Last
7.7¢
  Change
0.002 ( 0.00 %)
Open High Low Volume
7.5¢ 8.0¢ 7.3¢ 161454
Last updated 15.34pm 28/03/2024 ?
BIT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.